Should You Buy Rocket Lab While It's Below $40?

Rocket Lab (RKLB) shares have soared nearly 600% over the past year, reaching a $15 billion market capitalization, fueled by investor optimism for its rocket launch and expanding space systems segments, which aim to compete with SpaceX. Despite this significant appreciation and the potential of its larger Neutron rocket, the company faces substantial risks including ongoing unprofitability with $177 million in annual free cash flow burn, the untested status of the Neutron, and an extremely high trailing price-to-sales ratio of 36. These factors lead to an assessment of significant overvaluation, suggesting the stock should be avoided.

Analysis

Rocket Lab (RKLB) has experienced a significant valuation expansion, with its stock appreciating nearly 600% over the last 12 months to reach a $15 billion market capitalization. This surge is fueled by its strategic position as a primary competitor to SpaceX, anchored by its proven Electron rocket program—which recently completed its 65th launch—and the anticipated 2025 debut of its larger Neutron rocket. Critically, the company's Space Systems segment, which includes satellite components, already constitutes the majority of its business, contributing over 70% of Q1 revenue. Despite this operational progress, the company faces substantial financial and execution risks. It remains unprofitable, with an annual free cash flow burn of $177 million against a cash balance of just over $500 million, raising potential liquidity concerns. Furthermore, the company's valuation appears stretched, trading at a trailing price-to-sales ratio of 36. This multiple suggests the market has already priced in flawless execution of the untested Neutron rocket and a path to profitability that is both distant and uncertain, given current gross margins below 30%.

Key Decisions for Investors

• Investors should exercise caution due to the stock's extreme valuation, as its $15 billion market cap and 36x trailing P/S ratio appear to have priced in years of successful growth and flawless execution of the unproven Neutron rocket.
• Closely monitor the company's cash burn rate of $177 million annually against its ~$500 million cash reserve, as any delays or costly failures in the Neutron development program could accelerate liquidity risks.
• For those holding the stock after its 600% run-up, it may be prudent to consider the elevated risk-reward profile and re-evaluate the position, while new investors should be aware that the current price may not offer a favorable entry point given the fundamental uncertainties.